Please login to the form below
trial failure
This page shows the latest trial failure news and features for those working in and with pharma, biotech and healthcare.
Biogen’s highly-anticipated Alzheimer’s drug wins FDA fast-track
Biogen maintained that failure in the second trial of aducanumab was likely due to the fact that there weren’t a sufficient number of patients receiving enough exposure to the higher
Latest news
-
Boehringer/Lilly's Jardiance hits the mark in pivotal heart failure trial
The EMPEROR-Reduced trial evaluated SGLT2 inhibitor Jardiance (empagliflozin) in patients with heart failure with reduced ejection fraction (HFrEF). ... Aside from the EMPEROR-Reduced trial, Boehringer/Lilly is also investigating Jardiance as a treatment
-
Merck, Bayer flesh out vericiguat heart failure data at ACC
Drug reduced rate of cardiovascular deaths and hospitalisations. Bayer and Merck &Co have unveiled the data from their phase 3 trial of vericiguat in high-risk heart failure, backing up a ... The patients in the trial were well treated, with more than a
-
AstraZeneca’s Imfinzi fails first-line bladder cancer test
a setback with the failure of the phase 3 DANUBE trial. ... Previously-untreated bladder cancer is split roughly 50:50 between patients who can and cannot be treated with chemotherapy, and the DANUBE trial enrolled subjects in both categories.
-
Trial of Amgen, Servier’s heart failure drug clears interim check
Drug could become a $2bn product if approved. Amgen and Servier are creeping closer to a readout on their first-in-class chronic heart failure drug omecamtiv mecarbil, after their phase ... Other drugs in the SGLT2 class – including Boehringer
-
Teva’s weak pipeline hit by Tourette’s drug trial failure
It’s not the first drug in the VMAT2 inhibitor class to miss the mark in a Tourette’s trial, however. ... 110 and Otsuka’s well-established antipsychotic drug Abilify (aripiprazole), which is in a trial with data due next year.
More from news
Approximately 26 fully matching, plus 73 partially matching documents found.
Latest Intelligence
-
COVID-19: the race to find a vaccine
A subsequent leak about the apparent failure of remdesivir in a Chinese trial then dampened expectations again. ... A clinical trial of Regeneron’s drug is scheduled to start in June.
-
For trials without tribulations, we must improve patient experience
The result of this consultation is Havas Lynx Group’s latest white paper‘Patient Centricity on Trial’. ... This kind of simple, practical question can be the difference between success and failure of a clinical trial, and is usually only raised by
-
VIDEO interview: Neil Weir, UCB
Avoiding failure. By taking this approach to research, it's possible to avoid one of the major pitfalls facing pharma today – the high cost of late-stage trial failure. ... Particularly when we have high failure rates in late stages in clinical studies,
-
Customer valuation in pharma
Multiple studies have pegged the probability of clinical trial success at between 13-20 per cent. ... This estimate has remained constant over decades. Among the major reasons for clinical trial failure are problems that rest squarely in the domain of
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Alzheimer's: the numbers we cannot forget
This is one of the highest clinical trial failure rates in healthcare. ... Failures in these trials have been associated with lack of efficacy, excessive side effects, or challenges in trial execution; leaving patients and HCPs with 5 therapies to choose
-
A forward march for adaptive designs
For example, poor dose selection in phase II is frequently cited as one of the top causes of late-stage clinical trial failure. ... As such, it has prioritised phase II/III adaptive trial designs as well as other types of study.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- New study identifies drugs that are safe to use in COVID-19 treatment
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- BMS eyes approval for second Opdivo combo in kidney cancer
- New medical communications agency BOLDSCIENCE launches
- Moderna inks R&D agreements with Vertex and Chiesi
- FDA hands BMS and bluebird bio a priority review for ide-cel
- Janssen’s EGFR-targeting treatment regimen shows early benefit in lung cancer
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Could formulary intelligence be your brand differentiator?
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Porterhouse Medical strengthens its senior management team
PMHub
McCann Health Medical Communications
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....
Latest intelligence
- Could formulary intelligence be your brand differentiator?
- Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
Quick links
Infographics
